These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21374318)

  • 1. Immunostimulatory CpG motifs and DNA vaccines.
    Weeratna R; Krieg AM; Davis HL
    Methods Mol Med; 2000; 29():169-72. PubMed ID: 21374318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides.
    Yi AK; Chace JH; Cowdery JS; Krieg AM
    J Immunol; 1996 Jan; 156(2):558-64. PubMed ID: 8543806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-stimulation with TLR3 and TLR21 ligands synergistically up-regulates Th1-cytokine IFN-γ and regulatory cytokine IL-10 expression in chicken monocytes.
    He H; Genovese KJ; Swaggerty CL; MacKinnon KM; Kogut MH
    Dev Comp Immunol; 2012 Apr; 36(4):756-60. PubMed ID: 22120532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.
    Krieg AM; Love-Homan L; Yi AK; Harty JT
    J Immunol; 1998 Sep; 161(5):2428-34. PubMed ID: 9725240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs?
    Verfaillie T; Cox E; Goddeeris BM
    Vet Immunol Immunopathol; 2005 Jan; 103(1-2):141-51. PubMed ID: 15626469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic applications of CpG-containing oligodeoxynucleotides.
    Klinman DM; Ishii KJ; Gursel M; Gursel I; Takeshita S; Takeshita F
    Drug News Perspect; 2000 Jun; 13(5):289-96. PubMed ID: 12937643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.
    Wattrang E; Berg M; Magnusson M
    Vet Immunol Immunopathol; 2005 Sep; 107(3-4):265-79. PubMed ID: 15955566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Up-to-date understanding of tuberculosis immunity].
    Mitsuyama M; Akagawa K; Kobayashi K; Sugawara I; Kawakami K; Yamamoto S; Okada Z
    Kekkaku; 2003 Jan; 78(1):51-5. PubMed ID: 12683337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice.
    Wu J; Ma H; Qu Q; Zhou WJ; Luo YP; Thangaraj H; Lowrie DB; Fan XY
    Vaccine; 2011 Oct; 29(44):7624-30. PubMed ID: 21856352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG motifs in bacterial DNA and their immune effects.
    Krieg AM
    Annu Rev Immunol; 2002; 20():709-60. PubMed ID: 11861616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of CpG motifs to the immunogenicity of DNA vaccines.
    Klinman DM; Yamshchikov G; Ishigatsubo Y
    J Immunol; 1997 Apr; 158(8):3635-9. PubMed ID: 9103425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model.
    Bertin S; Anjuere F; Gavelli A; Baque P; Soilihi BK; Brossette N; Loubat A; Pierrefite-Carle V
    Int J Mol Med; 2008 Mar; 21(3):309-15. PubMed ID: 18288378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development.
    Yamamoto S; Yamamoto T; Nojima Y; Umemori K; Phalen S; McMurray DN; Kuramoto E; Iho S; Takauji R; Sato Y; Yamada T; Ohara N; Matsumoto S; Goto Y; Matsuo K; Tokunaga T
    Jpn J Infect Dis; 2002 Apr; 55(2):37-44. PubMed ID: 12082305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides.
    Zelenay S; Elías F; Fló J
    Eur J Immunol; 2003 May; 33(5):1382-92. PubMed ID: 12731065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
    Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
    Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG DNA and LPS induce distinct patterns of activation in human monocytes.
    Hartmann G; Krieg AM
    Gene Ther; 1999 May; 6(5):893-903. PubMed ID: 10505115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
    Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
    Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    Ballas ZK; Rasmussen WL; Krieg AM
    J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.